RNAi Technology Market to Reach US$5.55 Billion by 2034, Driven by siRNA Therapeutics and Targeted Delivery Innovation

Dublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "RNAi Technology - Market Insights, Competitive Landscape, and Market Forecast - 2034" has been added to ResearchAndMarkets.com's offering.

The global RNAi technology market is projected to expand from USD 1.65 billion in 2025 to USD 5.55 billion by 2034, registering a compound annual growth rate of 14.4% from 2026 to 2034. Market growth is being supported by an expanding portfolio of approved small interfering RNA therapeutics, advances in targeted delivery technologies, increasing pharmaceutical investment, and the widespread adoption of RNA interference platforms in drug discovery and functional genomics.

RNAi Technology Market Highlights

• Small interfering RNA accounted for approximately 68% of the RNAi technology market in 2025.
• Drug discovery and development represented 69% of market revenue in 2025.
• GalNAc conjugates led the delivery technology segment with a 46% market share.
• Pharmaceutical and biotechnology companies generated 64% of market revenue.
• North America held the largest regional share at 45% in 2025.
• Asia-Pacific is expected to record the fastest growth through 2034.

Approved siRNA Therapeutics Strengthen Commercial Growth

The expanding number of approved siRNA therapeutics is a primary driver of the RNAi technology market. More than ten siRNA-based medicines have reached regulatory approval, strengthening clinical confidence in RNAi platforms across rare genetic, hepatic, cardiometabolic, and hematologic disorders. Commercial products targeting transthyretin amyloidosis, acute hepatic porphyria, primary hyperoxaluria, elevated cholesterol, and hemophilia demonstrate the growing therapeutic reach of the modality.

In March 2025, Alnylam Pharmaceuticals received U.S. Food and Drug Administration approval for AMVUTTRA (vutrisiran) for cardiomyopathy associated with transthyretin-mediated amyloidosis. The approval expanded RNAi into a major cardiovascular indication. During the same month, Qfitlia (fitusiran) entered the U.S. market for hemophilia A or B, with or without inhibitors, further illustrating the diversification of RNAi therapeutic applications.

Targeted Delivery Technologies Expand RNAi Applications

Innovation in RNAi delivery remains central to market development. GalNAc conjugation has established a leading position in liver-directed delivery, supporting subcutaneous administration, improved tissue targeting, and extended dosing intervals. Lipid nanoparticles continue to enable systemic delivery, while polymer carriers, viral vectors, ligand-conjugated systems, cell-penetrating peptides, and vesicle-based platforms are being evaluated for broader tissue access.

Development programs increasingly focus on extrahepatic delivery to the central nervous system, muscle, lung, heart, and other tissues. Progress in these areas could significantly increase the number of addressable diseases and create new opportunities for RNAi therapeutics beyond established liver-directed programs.

RNAi Technology Market Segment Analysis

By molecule type, the siRNA segment generated approximately 68% of market revenue in 2025. Its leadership is supported by a growing commercial portfolio, strong late-stage clinical activity, high Target specificity, and compatibility with established delivery technologies. MicroRNA and short hairpin RNA platforms remain important in oncology research, disease modeling, Target validation, and functional genomics.

By application, drug discovery and development held a 69% market share in 2025. Pharmaceutical companies, biotechnology developers, and research institutions use RNAi screening and gene-silencing platforms to evaluate biological pathways, validate therapeutic targets, prioritize drug candidates, and support preclinical development. Therapeutic applications are also expanding as approved products enter larger patient populations and new clinical indications.

GalNAc conjugates led the delivery technology segment with a 46% share in 2025. Their established performance in liver-directed delivery has made them a preferred platform for multiple clinical and commercial programs. Lipid nanoparticles represent another major category, while investment in polymer carriers, viral vectors, and Next -generation delivery systems is expected to increase throughout the forecast period.

Pharmaceutical and biotechnology companies accounted for 64% of the RNAi technology market by end user. These organizations lead therapeutic discovery, clinical development, manufacturing, regulatory activity, and commercialization. Academic institutions remain essential contributors to functional genomics and Target discovery, while contract research and manufacturing organizations are benefiting from rising demand for oligonucleotide synthesis, analytical services, formulation, clinical support, and commercial-scale production.

Regional RNAi Technology Market Outlook

North America dominated the global RNAi technology market with a 45% revenue share in 2025. The region benefits from extensive biotechnology investment, advanced research infrastructure, active clinical development, regulatory experience, and the presence of major RNAi companies. The United States remains the primary contributor, supported by organizations including Alnylam Pharmaceuticals , Arrowhead Pharmaceuticals, and Ionis Pharmaceuticals, as well as leading academic centers and life-science suppliers.

Europe represents a significant RNAi technology market, led by the United Kingdom, Germany, France, and Switzerland. Regional growth is supported by advanced biomedical research, established regulatory pathways, rare-disease initiatives, and investment in cardiometabolic and genetic medicine programs.

Asia-Pacific is forecast to be the fastest-growing regional market through 2034. China, Japan, South Korea, and India are increasing investment in precision medicine, genomics, biotechnology manufacturing, and clinical research. China has emerged as an important RNAi innovation center, supported by local developers, expanding trial activity, large patient populations, and strategic partnerships with multinational pharmaceutical companies.

Latin America, the Middle East, and Africa are expected to provide longer-term opportunities as genomics programs, healthcare investment, and research capabilities develop. Market adoption in these regions will remain influenced by infrastructure, reimbursement, manufacturing access, and regulatory capacity.

Market Challenges and Competitive Dynamics

Despite its strong growth outlook, the RNAi technology market faces challenges involving extrahepatic delivery, manufacturing complexity, treatment costs, reimbursement, dosing optimization, off- Target activity, immune responses, and long-term safety monitoring. Regulatory requirements for advanced nucleic acid therapeutics continue to evolve, while competition from antisense oligonucleotides, gene therapy, and gene-editing technologies is intensifying.

The competitive landscape remains consolidated because proprietary delivery systems, intellectual property, clinical validation, and manufacturing expertise create significant entry barriers. Alnylam Pharmaceuticals maintains a leading position through its approved portfolio and development pipeline. Other prominent participants include Arrowhead Pharmaceuticals, Novo Nordisk through Dicerna, Silence Therapeutics, Novartis , Ionis Pharmaceuticals, Thermo Fisher Scientific , Merck KGaA KGaA, Sirnaomics, and Sanofi.

Strategic partnerships, acquisitions, licensing agreements, and research collaborations are shaping market competition. Leading companies are prioritizing extrahepatic delivery, optimized siRNA design, expansion into common diseases, manufacturing scalability, and combinations with complementary therapeutic modalities.

RNAi Technology Market Segmentation

• By molecule type: siRNA, miRNA, shRNA, and other RNAi molecules.
• By application: drug discovery and development, therapeutics, and functional genomics.
• By delivery technology: GalNAc conjugates, lipid nanoparticles, polymer and other carriers, and viral vectors.
• By therapeutic area: rare genetic disorders, cardiometabolic disorders, oncology, hepatic and infectious diseases, neurological disorders, and other indications.
• By end user: pharmaceutical and biotechnology companies, academic and research institutes, and contract research and manufacturing organizations.
• By geography: North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

RNAi Technology Market Outlook

The RNAi technology market is positioned for sustained double-digit growth through 2034. Clinical validation, targeted delivery innovation, expanding pipelines, pharmaceutical partnerships, and continued demand for RNAi in drug discovery will support long-term market development. Although delivery beyond the liver and treatment affordability remain important barriers, advances in platform design and manufacturing are expected to broaden therapeutic access and strengthen the commercial potential of RNAi technologies worldwide.

A selection of companies mentioned in this report includes, but is not limited to:

• Alnylam Pharmaceuticals , Inc.
• Arrowhead Pharmaceuticals, Inc.
• Novo Nordisk A/S (Dicerna)
• Silence Therapeutics plc
• Novartis AG
• Ionis Pharmaceuticals, Inc.
• Thermo Fisher Scientific .
• Merck KGaA KGaA
• Sirnaomics, Inc.
• Sanofi S.A.

For more information about this report visit https://www.researchandmarkets.com/r/i15mbn

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900